Clinical Trial Update: Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating PD-1 monoclonal antibody SHR-1210 in combination with apatinib for advanced non-small cell lung cancer, soft tissue sarcoma, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Soft Tissue Sarcoma
• Uterine Cancer

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Advanced Non Small Cell Lung Cancer, Uterine Cancer | Phase 2 | Status: UNKNOWN